COVID-19 大流行期间良性前列腺增生患者管理建议:314 例回顾性研究
该研究对 2020 年 1 月 24 日前在中南大学湘雅医院泌尿外科门诊确诊、疫情控制后返院复查的 314 例良性前列腺增生(BPH)患者进行电话随访,分析疫情期间的疾病管理。随访发现 245 例(79.3%)年龄超过 60 岁、187 例(60.5%)有基础疾病;47 例(15.2%)疫情期间就诊,其中 18 例到医院复诊、29 例经网络或电话咨询,11 例接受手术(3 例急诊手术)。65 例(24.4%)自行不规律用药、54 例(20.3%)自行调整剂量和药物种类。IPSS 中重度症状比例由 79.9% 升至 90.1%,QOL 评分≥5 比例由 82.5% 升至 88.9%,联合用药比例由 78.9% 升至 91.2%。作者认为 COVID-19 明显影响 BPH 治疗,建议条件允许时患者首选到医院评估,不能时医疗机构应提供电话或网络咨询,并尽早为有需要者安排手术治疗。
要点
- 314 例 BPH 随访中,IPSS 中重度症状比例由 79.9% 升至 90.1%,QOL 评分≥5 比例由 82.5% 升至 88.9%,提示疫情期间症状与生活质量负担加重。
- 65 例(24.4%)自行不规律用药、54 例(20.3%)自行调整剂量和药物种类,是疫情期间 BPH 管理中需要关注的问题。
- 仅 47 例(15.2%)疫情期间就诊(18 例到医院复诊、29 例经网络或电话咨询),而 302 例(97.7%)希望疫情期间复查。
- 11 例疫情期间接受手术,其中 3 例为急诊手术;作者建议尽早为有需要者安排手术治疗以避免延误。
- 到医院复诊的患者较接受网络或电话咨询的患者病情控制更好;46.6% 的患者选择到私立医疗机构随访。
适用人群与场景
- 2020 年 1 月 24 日前在中南大学湘雅医院泌尿外科门诊确诊、疫情控制后返院复查的 314 例良性前列腺增生(BPH)患者。
- 随访人群中 245 例(79.3%)年龄超过 60 岁,187 例(60.5%)有基础疾病。
诊断标准与关键阈值
- 采用国际前列腺症状评分(IPSS)量表评估症状,中重度症状比例由 79.9% 升至 90.1%。
- 生活质量(QOL)评分≥5 的比例由 82.5% 升至 88.9%。
- 前列腺特异性抗原(PSA)>4 ng/ml 的比例由 10.0% 升至 15.1%。
- 最大尿流率(Qmax)<15 ml/s 的比例由 82.5% 升至 92.3%,Qmax<10 ml/s 的比例由 8.7% 升至 15.4%。
- 前列腺体积>30 ml 的比例由 94.1% 升至 97.0%;膀胱残余尿量>10 ml 的比例由 81.6% 升至 89.3%。
处置流程与药物剂量
- 作者建议:条件允许时,患者首先考虑到医院进行评估。
- 作者建议:无法到医院时,医疗机构应为 BPH 患者提供电话或网络咨询。
- 作者建议:应尽早为有手术需要的患者安排手术治疗,以避免延误治疗。
- 治疗构成变化:等待观察比例由 13.9% 降至 4.4%,等待手术比例由 4.9% 升至 16.4%,联合用药比例由 78.9% 升至 91.2%。
红旗征与不能漏的情况
- 下尿路症状(LUTS)中储尿期、排尿期和排尿后症状比例分别由 77.3%、21.7%、18.8% 升至 91.9%、27.5%、25.5%。
- 血尿比例由 0.9% 升至 2.3%,尿潴留比例由 0.6% 升至 1.7%。
- 11 例疫情期间接受手术,其中 3 例为急诊手术。
研究设计与关键结果
- 研究类型:回顾性研究;样本量 314 例;人群为 2020 年 1 月 24 日前在中南大学湘雅医院泌尿外科门诊确诊的 BPH 患者;方法为电话随访及疫情控制后返院复查。
- 随访发现 245 例(79.3%)年龄超过 60 岁,187 例(60.5%)有基础疾病;47 例(15.2%)疫情期间就诊,其中 18 例到医院复诊、29 例经网络或电话咨询;11 例接受手术(3 例急诊手术)。
- 65 例(24.4%)自行不规律用药,54 例(20.3%)自行调整剂量和药物种类;302 例(97.7%)希望疫情期间复查。
- IPSS 中重度症状比例由 79.9% 升至 90.1%,QOL 评分≥5 比例由 82.5% 升至 88.9%;储尿期、排尿期、排尿后症状比例分别由 77.3%、21.7%、18.8% 升至 91.9%、27.5%、25.5%;血尿和尿潴留比例分别由 0.9%、0.6% 升至 2.3%、1.7%。
- PSA>4 ng/ml 比例由 10.0% 升至 15.1%;Qmax<15 ml/s 比例由 82.5% 升至 92.3%,Qmax<10 ml/s 比例由 8.7% 升至 15.4%;前列腺体积>30 ml 比例由 94.1% 升至 97.0%;膀胱残余尿量>10 ml 比例由 81.6% 升至 89.3%;查体发现前列腺结节比例由 1.0% 升至 1.7%。
- 未发现前列腺癌患者;联合用药比例由 78.9% 升至 91.2%;与接受网络或电话咨询的患者相比,到医院复诊的患者病情控制更好;46.6% 的患者选择到私立医疗机构随访。
证据类型、等级与局限
- 证据类型:回顾性研究(电话随访及返院复查分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议:条件允许时 BPH 患者首先考虑到医院评估;无法到医院时,医疗机构应提供电话或网络咨询。
- 作者建议:应尽早为有手术需要的患者安排手术治疗,以避免延误。
- 研究提示:到医院复诊的患者较接受网络或电话咨询的患者病情控制更好。
指南或共识出处
- Biomed Res Int 发表的《COVID-19 大流行期间良性前列腺增生患者管理建议:314 例回顾性研究》。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Through investigation and analysis of the course management of 314 patients with benign prostatic hyperplasia (BPH) during the COVID-19 pandemic, we expected to offer effective recommendations for the management of patients with BPH against the background of the COVID-19 pandemic.
METHODS: We implemented telephone follow-ups of 314 patients with BPH who were diagnosed at the Urology Clinic of Xiangya Hospital of Central South University before January 24, 2020, and who were admitted to the hospital for reexamination after the epidemic was controlled in China, and we conducted research and analysis of their disease management during the COVID-19 pandemic.
RESULTS: In the follow-up, we found 245 patients (79.3%) over 60 years of age and 187 patients (60.5%) with underlying disease. There were 47 patients (15.2%) who returned for consultation during the COVID-19 pandemic, and of these, 18 were admitted to the hospital for follow-up consultation, and 29 patients underwent consultation via the internet or telephone. Eleven patients underwent surgery during the pandemic, and of these, three experienced emergency surgery. We encountered 65 patients (24.4%) who self-administered medications irregularly and 54 patients (20.3%) who self-medicated and adjusted the dosage and drug types themselves. There were 302 patients (97.7%) who wished to be reexamined during the COVID-19 pandemic. In terms of treatment, the proportion of patients "awaiting observation" declined from 13.9% to 4.4%, and the proportion of patients "awaiting surgery" increased from 4.9% to 16.4%. Using the International Prostate Symptom Score (IPSS) scale, the percentage of patients with moderate-to-severe symptoms increased from 79.9% to 90.1%, and the proportion with a quality of life (QOL) score ≥ 5 rose from 82.5% to 88.9%. The proportions of patients exhibiting storage, voiding, and postmicturition symptoms in lower urinary tract symptoms (LUTS) increased from 77.3%, 21.7%, and 18.8% to 91.9%, 27.5%, and 25.5%, respectively; those manifesting hematuria and urinary retention increased from 0.9% and 0.6% to 2.3% and 1.7%, respectively; those with a prostate specific antigen (PSA) > 4 ng/ml rose from 10.0% to 15.1%; patients with a maximum flow rate (Qmax) < 15 ml/s increased from 82.5% to 92.3%, and the proportion with a Qmax < 10 ml/s increased from 8.7% to 15.4%; the individuals with a prostate volume > 30 ml increased from 94.1% to 97.0%; the percentage of men with a bladder residual urine volume > 10 ml was augmented from 81.6% to 89.3%, and patients with prostate nodules on physical examination were elevated from 1.0% to 1.7%. We uncovered no prostate cancer in patients, and the proportion of patients administered the combination drug increased from 78.9% to 91.2%. Compared with patients receiving online or telephone consultations, patients undergoing reexamination at the hospital were better controlled. When we conducted a survey of whether patients chose to go to a public or private hospital for follow-up, we found that 46.6% of the patients chose to go to a private medical institution.
CONCLUSIONS: COVID-19 greatly affected the treatment of patients with BPH. When conditions permit, we recommend that patients first consider going to the hospital for evaluation; however, when this is not possible, medical institutions should provide telephone or online consultation for patients with BPH. Surgical treatment should also be arranged for those in need as soon as possible to avoid delaying the patient's treatment.
参考来源
- Ding K, Tang R, Yu J, et al. Recommendations for the Management of Patients with Benign Prostatic Hyperplasia in the Context of the COVID-19 Pandemic: A Retrospective Study of 314 Cases. Biomed Res Int. 2022. PMID: 35607311. doi:10.1155/2022/5739574
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。